Cancer Research

Cancer patient receives chemotherapy via IV
#Cancer research #Clinical trial #kainova #Solid tumours

Positive results announced for metastatic tumour treatment 

A new anti-tumour treatment for metastatic solid tumours has achieved encouraging results in a Phase I clinical trial.  DT-9081, developed by biopharmaceutical company Kainova Therapeutics, is a proprietary, oral small molecule EP4 receptor (EP4R) antagonist in patients with advanced, recurrent, and metastatic solid tumours.  According to Kainova, the… Read More

#Cancer Research #News

#Brain #Institute of Cancer Research #Tumour biology

Brain imaging platform could ‘accelerate’ tumour treatment 

An advanced imaging platform could “accelerate” the treatment of childhood brain tumours, research reveals.  Scientists at The Institute of Cancer Research, London have developed a new preclinical platform for studying aggressive childhood brain tumours, using advanced imaging to show how closely experimental models mirror the disease seen… Read More

#Cancer Research #News

Tumour microenvironment
#Insilico Medicine #KRAS #Oncology #Solid tumours

Insilico Medicine nominates pan-KRAS preclinical candidate

Insilico Medicine has nominated ISM6166 as a preclinical candidate, a potent, oral pan-KRAS inhibitor designed to treat a broad spectrum of solid tumours.  Among the Ras family of oncogenes, KRAS is one of the most frequently altered drivers in human cancer, playing a key role in regulating… Read More

#Cancer Research #News

Female scientists conducting research on samples
#Nuclear medicine #Prostate cancer

EANM launches award for prostate cancer research 

The European Association of Nuclear Medicine (EANM) has launched an award for research in prostate cancer treatment.  The 2026 EANM Young Scientist Network Award, aiming to accelerate innovation in alpha radioligand therapy in prostate cancer, offers three prizes of €40,000 (Platinum), €20,000 (Gold) and €10,000 (Silver). … Read More

#Cancer Research #News

Ovarian cancer cells
#Cancer research #European Innovation Council #Ovarian cancer #Women's health

EIC awards €2.5m grant for gynaecological cancer drug 

The European Innovation Council (EIC) has awarded €2.5 million to biotechnology company Step Pharma to accelerate the development of dencatistat for CTPS2 null gynaecological tumours.  The funding, which consists of a €2.5 million grant and potentially up to €10 million in equity investment, is part of the EIC’s Accelerator Award,… Read More

#Cancer Research #News #Regulatory

Blood cancer
#Myeloma #Oncology #Phase II trial #Starton Therapeutics

STAR-LLD seeks to replace standard care for blood cancers

Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM).  STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple… Read More

#Cancer Research #News

Ovarian cancer cells
#Clinical trial #Oncology #Ovarian cancer

Ovarian cancer treatment could prevent peritoneal recurrence 

A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests.  Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More

#Cancer Research #News

#Cancer Research Horizons #Genome sequencing #RNA sequencing #UK

Oesophageal cancer dataset made available for commercial use 

Cancer Research Horizons has made one the largest oesophageal cancer datasets available for commercial licensing.  Developed by a team led by Professor Rebecca Fitzgerald at the University of Cambridge, the Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) dataset represents one of the world’s largest and most comprehensive collections… Read More

#Cancer Research #News

CAR-T cells attacking a cancer cell
#Advanced Therapies #CAR-T #Cell therapy #Lyell Immunopharma #Lymphoma #Oncology #Phase III trial

CAR-Ts go head-to-head in first-of-its-kind clinical trial

Lyell Immunopharma has begun its PiNACLE – H2H Phase III trial evaluating rondecabtagene autoleucel (ronde-cel, also known as LYL314) compared to lisocabtagene maraleucel (liso-cel) or axicabtageneciloleucel (axi-cel).  The CAR-T therapies will be assessed in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) receiving treatment in the second-line… Read More

#Cancer Research #News #Trending News

Molecular glues
#Molecular glue degrader #Neomorph #Oncology #Phase I trial

Novel molecular glue degrader therapy reaches first patients

Neomorph has commenced a Phase I/II clinical trial evaluating NEO-811, a novel investigational molecular glue degrader, in patients with locally advanced or metastatic non-resectable clear cell renal cell carcinoma (ccRCC).  NEO-811 is an investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein… Read More

#Cancer Research #News

#Blood cancer #Cancer Research UK #UK

Cancer Research UK invests £2.5m in blood cancer care 

Cancer Research UK has allocated £2.5 million ($3.4 million) to researchers at the University of York to help transform care for patients diagnosed with blood cancers.  The funding is for the world leading Haematological Malignancy Research Network (HMRN), one of the most comprehensive blood cancer research networks in the… Read More

#Cancer Research #News

London cancer hub
#Cancer research #Institute of Cancer Research #Lab space #London Cancer Hub #The Royal Marsden NHS Foundation Trust

London Cancer Hub secures approval for £1bn expansion plans 

The London Cancer Hub has secured approval for a £1 billion ($1.4 billion) expansion, bringing state-of-the-art cancer research and lab space to the UK.   London Cancer Hub’s expanded district promises to be one of the world’s most ambitious life sciences clusters, with 12 acres dedicated to accelerating cancer research, treatment and commercial… Read More

#Cancer Research #News

Nucleolus of the cell
#Cancer treatment #Oncology #RNA #Texas A&M University Health Science Center

Researchers identify RNA linked to cancer survival

Researchers at the Texas A&M University Health Science Center have identified a novel RNA molecule that plays a crucial role in preserving the integrity of a key cellular structure, nucleolus.  This research reveals an RNA molecule that regulates key cellular functions without turning into protein, thus functioning… Read More

#Cancer Research #Editor's Choice #News